ECSP045467A - Nuevos anticuerpos dirigidos contra factores tisulares como anticoagulantes - Google Patents

Nuevos anticuerpos dirigidos contra factores tisulares como anticoagulantes

Info

Publication number
ECSP045467A
ECSP045467A EC2004005467A ECSP045467A ECSP045467A EC SP045467 A ECSP045467 A EC SP045467A EC 2004005467 A EC2004005467 A EC 2004005467A EC SP045467 A ECSP045467 A EC SP045467A EC SP045467 A ECSP045467 A EC SP045467A
Authority
EC
Ecuador
Prior art keywords
tissular
anticoagulants
factors
directed against
antibodies directed
Prior art date
Application number
EC2004005467A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045467(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ECSP045467A publication Critical patent/ECSP045467A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Nuevos anticuerpos que se unen con mayor afinidad al complejo del factor VIIa/factor tisular (FVIIa/TF) que al factor tisular (TF) solamente, no compiten por la unión a TF con FVII y FX e inhiben la activación de FX. Los anticuerpos se unen en el sitio de la lesión y previenen el inicio de trombosis. Los anticuerpos se pueden usar para el tratamiento de diversas afecciones trombóticas incluyendo, a modo de ejemplo, trombosis de venas profundas, coagulación intravascular diseminada y síndrome coronario agudo.
EC2004005467A 2002-05-01 2004-11-30 Nuevos anticuerpos dirigidos contra factores tisulares como anticoagulantes ECSP045467A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37656602P 2002-05-01 2002-05-01

Publications (1)

Publication Number Publication Date
ECSP045467A true ECSP045467A (es) 2005-01-28

Family

ID=29401364

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2004005467A ECSP045467A (es) 2002-05-01 2004-11-30 Nuevos anticuerpos dirigidos contra factores tisulares como anticoagulantes
EC2004005468A ECSP045468A (es) 2002-05-01 2004-11-30 Nuevas proteínas de fusión con trombomodulina dirigidas contra factores tisulares como anticoagulantes

Family Applications After (1)

Application Number Title Priority Date Filing Date
EC2004005468A ECSP045468A (es) 2002-05-01 2004-11-30 Nuevas proteínas de fusión con trombomodulina dirigidas contra factores tisulares como anticoagulantes

Country Status (29)

Country Link
US (3) US7250168B2 (es)
EP (2) EP1549341B1 (es)
JP (2) JP4567437B2 (es)
KR (2) KR101080587B1 (es)
CN (2) CN100563709C (es)
AR (1) AR039515A1 (es)
AT (2) ATE427121T1 (es)
AU (2) AU2003225255B2 (es)
BR (2) BR0304660A (es)
CA (2) CA2483909A1 (es)
CR (1) CR7584A (es)
DE (2) DE60334538D1 (es)
DK (2) DK1503785T3 (es)
EC (2) ECSP045467A (es)
ES (2) ES2354419T3 (es)
HK (1) HK1080372A1 (es)
IL (3) IL164733A0 (es)
MX (2) MXPA04010795A (es)
NO (2) NO20035848L (es)
NZ (2) NZ536242A (es)
PE (1) PE20040597A1 (es)
PL (2) PL373945A1 (es)
PT (2) PT1549341E (es)
RS (2) RS102404A (es)
RU (2) RU2320366C2 (es)
TW (1) TWI343388B (es)
UA (2) UA81114C2 (es)
WO (2) WO2003093422A2 (es)
ZA (2) ZA200409692B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
DE60025241T2 (de) * 1999-09-27 2007-01-11 Chugai Seiyaku K.K. HäMOPOIETINREZEPTOR-PROTEIN, NR12
CA2425208C (en) 2000-09-26 2013-04-09 Duke University Rna aptamers and methods for identifying the same
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
KR101080587B1 (ko) * 2002-05-01 2011-11-04 바이엘 파마 악티엔게젤샤프트 항응고제로서의 신규 조직 인자 표적화된 항체
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7833978B2 (en) * 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
SI1745062T1 (sl) 2004-04-22 2014-09-30 Regado Biosciences, Inc. Izobljšani modulatorji koagulacijskih faktrojev
CN103665168A (zh) * 2005-06-03 2014-03-26 持田制药株式会社 抗cd14抗体融合蛋白质
US20090130104A1 (en) * 2005-10-05 2009-05-21 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
ATE485052T1 (de) * 2006-04-07 2010-11-15 Novo Nordisk Healthcare Ag Kovalenter faktor vii-gewebefaktor-komplex
CL2007001665A1 (es) 2006-06-08 2008-01-18 Chugai Pharmaceutical Co Ltd Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
CN101522206B (zh) * 2006-10-06 2013-03-27 旭化成制药株式会社 弥散性血管内凝血综合征的治疗剂和/或改善剂
WO2008121814A1 (en) * 2007-03-28 2008-10-09 Ats Medical, Inc. Method for inhibiting platelet interaction with biomaterial surfaces
CA2700293A1 (en) * 2007-09-20 2009-03-26 Bracco Imaging Spa Method for the preparation of new oligoclonal antibodies
MY185647A (en) 2007-12-05 2021-05-27 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
US8333973B2 (en) * 2008-01-02 2012-12-18 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
AU2009282234A1 (en) * 2008-08-14 2010-02-18 Merck Sharp & Dohme Corp. Methods for purifying antibodies using protein a affinity chromatography
WO2010045518A1 (en) * 2008-10-16 2010-04-22 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2230251A1 (en) * 2009-03-19 2010-09-22 Bracco Imaging S.p.A Antibodies specifically active in the coronary plaque and method for their identification
WO2011026000A1 (en) * 2009-08-28 2011-03-03 Bayer Healthcare Llc Cofactors for thrombin activation of factor vii and uses thereof
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
CN107188970A (zh) * 2010-06-04 2017-09-22 株式会社蒂奥姆生物 具有因子vii活性的融合蛋白质
AU2011267106B2 (en) 2010-06-15 2015-05-14 Genmab A/S Human antibody drug conjugates against tissue factor
WO2012017310A2 (en) * 2010-08-05 2012-02-09 Council Of Scientific & Industrial Research Protein fusion constructs possessing thrombolytic and anticoagulant properties
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
WO2016176440A2 (en) * 2015-04-28 2016-11-03 Saint Louis University Thrombin-thrombomodulin fusion proteins as protein c activators
US11085031B2 (en) 2016-04-28 2021-08-10 Saint Louis University Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant
MX2019005693A (es) * 2016-11-16 2019-08-14 Bayer Healthcare Llc Factor viii direccionado a los globulos rojos y metodo para su uso.
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CA3099547A1 (en) 2018-05-07 2019-11-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
CN112840032A (zh) * 2018-10-04 2021-05-25 血栓形成和凝血公司 用于确定蛋白水平的方法
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
EP4062933A4 (en) 2019-11-20 2023-12-13 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
CN114686443B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用
CN114686444B (zh) * 2020-12-31 2024-05-31 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US4912207A (en) * 1987-05-06 1990-03-27 Washington University DNA clone of human thrombomodulin and portions thereof
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
AU646633B2 (en) * 1989-02-17 1994-03-03 Codon Soluble analogs of thrombomodulin
US5256770A (en) * 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
US5466668A (en) * 1989-04-28 1995-11-14 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
KR930008093B1 (ko) * 1990-08-03 1993-08-25 아사히가세이고오교 가부시끼가이샤 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
JPH0578397A (ja) * 1991-01-29 1993-03-30 Sumitomo Pharmaceut Co Ltd 血栓溶解タンパク質
JPH06133780A (ja) * 1992-10-23 1994-05-17 Sumitomo Pharmaceut Co Ltd 新規なｔ−ＰＡ改変体
US5916874A (en) * 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
AU752730B2 (en) * 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
AU5081401A (en) * 2000-03-16 2001-10-03 Genentech Inc Anti-tissue factor antibodies with enhanced anticoagulant potency
US6632791B1 (en) * 2000-06-21 2003-10-14 Schering Aktiengesellschaft Thrombomodulin analogs for pharmaceutical use
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
AU2003201159A1 (en) 2002-01-08 2003-07-24 Bayer Healthcare Ag Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
KR101080587B1 (ko) * 2002-05-01 2011-11-04 바이엘 파마 악티엔게젤샤프트 항응고제로서의 신규 조직 인자 표적화된 항체
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants

Also Published As

Publication number Publication date
PE20040597A1 (es) 2004-10-06
MXPA04010851A (es) 2005-02-14
NZ536243A (en) 2006-06-30
CN100412090C (zh) 2008-08-20
US7250168B2 (en) 2007-07-31
EP1549341A2 (en) 2005-07-06
ES2354419T3 (es) 2011-03-14
RU2320366C2 (ru) 2008-03-27
RS102404A (sr) 2006-12-15
BR0304659A (pt) 2004-09-21
EP1549341A4 (en) 2006-10-18
DK1503785T3 (da) 2011-02-07
TWI343388B (en) 2011-06-11
AU2003225255B2 (en) 2008-07-31
KR20050045944A (ko) 2005-05-17
KR20050045945A (ko) 2005-05-17
NO20035849L (no) 2004-02-27
ATE484524T1 (de) 2010-10-15
EP1503785A2 (en) 2005-02-09
AU2003225256A1 (en) 2003-11-17
EP1503785B1 (en) 2010-10-13
PT1549341E (pt) 2009-05-29
IL164733A (en) 2011-05-31
RU2004135306A (ru) 2005-07-10
ATE427121T1 (de) 2009-04-15
JP2005538046A (ja) 2005-12-15
ECSP045468A (es) 2005-01-28
ZA200409692B (en) 2006-07-26
US7622122B2 (en) 2009-11-24
AU2003225255A1 (en) 2003-11-17
ZA200409694B (en) 2006-02-22
NO20035848L (no) 2004-02-27
NZ536242A (en) 2006-04-28
EP1549341B1 (en) 2009-04-01
KR101013697B1 (ko) 2011-02-10
IL164732A0 (en) 2005-12-18
DE60326970D1 (de) 2009-05-14
PL373945A1 (en) 2005-09-19
TW200307043A (en) 2003-12-01
PL210582B1 (pl) 2012-02-29
AR039515A1 (es) 2005-02-23
DK1549341T3 (da) 2009-07-06
ES2323056T3 (es) 2009-07-06
RS104504A (sr) 2007-02-05
WO2003092602A2 (en) 2003-11-13
RU2004135308A (ru) 2005-08-10
CN100563709C (zh) 2009-12-02
UA85996C2 (ru) 2009-03-25
IL164733A0 (en) 2005-12-18
JP2005532045A (ja) 2005-10-27
CN1665526A (zh) 2005-09-07
RU2345789C2 (ru) 2009-02-10
AU2003225256B2 (en) 2009-06-04
WO2003093422A2 (en) 2003-11-13
EP1503785A4 (en) 2007-02-14
HK1080372A1 (zh) 2006-04-28
PT1503785E (pt) 2011-01-17
CA2483909A1 (en) 2003-11-13
CA2483910A1 (en) 2003-11-13
WO2003092602A3 (en) 2004-08-26
US20040063632A1 (en) 2004-04-01
JP4567437B2 (ja) 2010-10-20
WO2003093422A3 (en) 2004-07-15
DE60334538D1 (de) 2010-11-25
CR7584A (es) 2006-05-30
US20080019985A1 (en) 2008-01-24
CN1665534A (zh) 2005-09-07
PL373960A1 (en) 2005-09-19
JP4460443B2 (ja) 2010-05-12
MXPA04010795A (es) 2005-03-07
US7622457B2 (en) 2009-11-24
KR101080587B1 (ko) 2011-11-04
US20080020965A1 (en) 2008-01-24
UA81114C2 (en) 2007-12-10
BR0304660A (pt) 2005-06-07

Similar Documents

Publication Publication Date Title
ECSP045467A (es) Nuevos anticuerpos dirigidos contra factores tisulares como anticoagulantes
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
BRPI0419206A (pt) artigo absorvente
BR112023021913A2 (pt) Tratamento de câncer com inibidor de raf
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
CL2019001047A1 (es) Metodo para evitar eventos cardiovasculares mediante la reduccion de la proproteinas convertasa subtilisina kexina 9 (pcsk9).
WO2010056765A3 (en) Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
AR032643A1 (es) Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares
AR032403A1 (es) Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares
BRPI0516764B8 (pt) hemostato
CY1110889T1 (el) C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους
CY1112356T1 (el) Καλτσα
DE502005005659D1 (de) Verkürzte wundheilungsprozesse mittels neuartiger faservliese
ATE442101T1 (de) Vorrichtung und kit zur behandlung von stírungen des herzrhythmus-regulierungssystems
DE502005006931D1 (de) Fingerprotektor und damit ausgerüsteter Sporthandschuh
ATE475414T1 (de) Tuberkulosebehandlung mit pleuromutilinderivaten
DE60325175D1 (de) Vaskuläre okklusionsvorrichtung
ATE451077T1 (de) Künstliches blutgefäss
TW200727797A (en) Garment and manufacturing method thereof
EA200300849A1 (ru) Способы лечения или профилактики кожных заболеваний с помощью cd2-связывающих агентов
WO2006114105A8 (en) Use of modified factor vii for treating bleeding
PE134799A1 (es) Derivados de carbohidrato
DE602007003844D1 (de) Antirutsch-aktivierungsglieder
CR7589A (es) Nuevos anticuerpos dirigidos contra factores tisulares como anticoagulantes
BRPI0607280A2 (pt) método de tratamento ou prevenção de capsulite adesiva em paciente com necessidade desse tratamento